v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 20,925 $ 11,447
General and administrative 8,937 1,468
Total operating expenses 29,862 12,915
Loss from operations (29,862) (12,915)
Other income:    
Interest income 2,481 482
Other income 149 33
Total other income, net 2,630 515
Loss before income taxes (27,232) (12,400)
Income tax benefit 0 0
Net loss (27,232) (12,400)
Net loss attributable to common stock, basic (30,011) (14,582)
Net loss attributable to common stock, diluted $ (30,011) $ (14,582)
Net loss per share of common stock, basic (in usd per share) $ (1.32) $ (19.79)
Net loss per share of common stock, diluted (in usd per share) $ (1.32) $ (19.79)
Weighted average common stock outstanding, basic (in shares) 22,704,124 736,933
Weighted average common stock outstanding, diluted (in shares) 22,704,124 736,933
Other comprehensive loss:    
Net unrealized losses on marketable securities $ (584) $ 0
Total other comprehensive loss (584) 0
Total comprehensive loss $ (27,816) $ (12,400)